 Prof. Antonio Bertoletti
Professor in Emerging Infectious Diseases Programme
Duke-NUS Medical School
Singapore |
Title:
Panel Discussion Moderator
Biography:
Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. His current research is focused on developing new immunological-based therapies (mRNA-based TCR-redirected T cells) for treating HBV chronic infection and Hepatocellular carcinoma and on the characterization of antiviral Immunity in chronic HBV patients. After the start of the COVID-19 pandemic, his laboratory has been also actively involved in the characterization of SARS-COV2 specific T cell immune response in COVID-19 and SARS convalescent and healthy individuals.
In 2015 he founded Lion TCR Pte (http://liontcr.com), a biotech company developing immune-based treatments for virus-related cancers (HBV-HCC and EBV-related malignancies) and chronic viral infections. This immune therapy utilizes T cell receptors engineered T cells targeting viral antigens expressed in cancer cells. The company has been the first to initiate and run clinical trials (Phase I and II) for the treatment of HBV-related HCC relapses in liver transplant patients and in primary HCC in Singapore and China.
|
